NCT01151033已完成2 期
A Clinical Evaluation of the ProNOVA XR Polymer Free Drug Eluting Coronary Stent System in the Treatment of Patients With de Novo Coronary Artery Lesions
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- KCRI
- 入组人数
- 50
- 试验地点
- 3
- 主要终点
- In-stent late luminal loss
研究概览
简要总结
The objective of this study is the assessment of the performance, safety and efficacy of the ProNOVA XR Polymer Free Drug Eluting Stent System in the treatment of patients with de novo native coronary artery lesions.
详细描述
This study is a prospective, single arm, multicenter registry of approximately 50 patients undergoing PCI with the ProNOVA Drug Eluting Coronary Stent System according to its Instructions for Use.
The purpose of this registry is the evaluation of the performance, safety and efficacy of ProNOVA XR DES in real-world patients. Following initial stent implantation, all patients will have clinical follow up at 30 days, at 6 and 12 months. Additionally all patients will have a angiographic F/U at 6 months to assess the late luminal loss by QCA measurements and the neointimal volume including stent apposition by intravascular ultrasound.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient must be at least 18 years of age.
- •Patient is able to verbally confirm understanding of risks, benefits and treatment alternatives of receiving the ProNOVA XR DES and she or her legally authorized representative provides written informed consent prior to any study related procedure, as approved by the appropriate Medical Ethics Committee of the respective clinical site.
- •Patient must have evidence of myocardial ischemia (e.g., stable or unstable angina, silent ischemia, positive functional study or a reversible change in the electrocardiogram (ECG) consistent with ischemia)
- •Patient must agree to undergo all required follow-up examinations.
- •Patients of childbearing potential must have had a negative pregnancy test within 7 days before treatment, and must not be nursing at the time of treatment.
- •Angiographic Inclusion Criteria:
- •Target lesions must be de novo lesions (no prior stent implant, no prior brachytherapy)
- •Target vessel reference diameter must be between 2.25 mm and 4.0 mm by visual estimate
- •Target lesion ≤ 28 mm in length by visual estimate
排除标准
- •Patient has other medical illness (e.g., cancer or congestive heart failure) or known history of substance abuse (alcohol, cocaine, heroin etc.) that may cause non-compliance with the clinical investigation plan, confound the data interpretation or is associated with a limited life expectancy (i.e., less than one year)
- •Patient has a known hypersensitivity or contraindication to aspirin, either heparin or bivalirudin, both clopidogrel and ticlopidine, cobalt, chromium, nickel, or contrast sensitivity that cannot be adequately pre-medicated
- •Participation in another device or drug study or has completed the follow-up phase of another study within the last 30 days
- •Patients judged to have a lesion that prevents complete inflation of an angioplasty balloon.
结局指标
主要结局
In-stent late luminal loss
时间窗: at 6 months after stent implantation
次要结局
- Clinically and non-clinically indicated target lesion revascularization(at 12 months)
- Clinically and non-clinically indicated target vessel revascularization(at 12 months)
- Incidence of total and cardiovascular death(at 12 months)
- Incidence of nonfatal myocardial infarction(at 12 months)
- Definite, probable, and possible stent thrombosis(at 12 months)
- In-stent and in-segment percent diameter stenosis (% DS)(at 6 months after stent implantation)
- In-stent and in-segment binary restenosis rate as assessed by QCA(at 6 months after stent implantation)
- In-stent and in-segment minimal luminal diameter (MLD)as assessed by QCA(at 6 months after stent implantation)
- In-stent and in-segment late luminal loss as assessed by QCA(at 6 months after stent implantation)
- Neointimal hyperplasia as assessed by intravascular ultrasound (IVUS)(at 6 months after stent implantation)
- Rate of incomplete stent apposition as assessed by intravascular ultrasound (IVUS)(at 6 months after stent implantation)
研究者
研究点 (3)
Loading locations...
相似试验
已完成
2 期
Short Term Effects of PRX-03140 in Patients With Mild Alzheimer's Disease Being Treated With AriceptAlzheimer's DiseaseNCT00384423Epix Pharmaceuticals, Inc.80
已完成
不适用
Use of J3 Bioscience Lubricating Intravaginal Ring VR101 to Relieve the Symptoms of Vaginal DrynessMenopause Related ConditionsPostmenopausal SymptomsNCT03150407J3 Bioscience, Inc.72
已完成
3 期
Polyprenols (Ropren) in Acute Coronary SyndromeAcute Coronary SyndromeNCT03122340Tomsk National Research Medical Center of the Russian Academy of Sciences70
已完成
2 期
A Study to Evaluate PROCRIT (Epoetin Alfa) for Maintenance Phase Treatment of Patients With Anemia Due to Chronic Kidney Disease (PROMPT)Chronic Renal InsufficiencyAnemiaNCT00307814Ortho Biotech Products, L.P.519
已完成
3 期
PROVIGIL® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy or Obstructive Sleep Apnea/Hypopnea SyndromeNarcolepsySleep Apnea, ObstructiveNCT00107848Cephalon280